Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2009) 20 S12.2

ECE2009 Symposia Growth factors and signaling networks in pituitary tumours (4 abstracts)

MAPK and PI3K/AKT pathways in pituitary tumorigenesis

Mehtap Cakir


Akdeniz University, Antalya, Turkey.


Mitogen-activated protein kinases (MAPK) are a family of serine/threonine kinases and are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation. In mammals, there are more than a dozen MAPK genes. The best known are the extracellular signal-regulated protein kinases (ERK1 and 2); c-Jun N-terminal kinases (JNK1-3); p38s (α, β, γ, δ) and ERK5. Aberrant regulation of MAPK cascades contribute to cancer and other human diseases. In particular, ERK 1/2 which is a downstream component of a signaling module that is activated by the Raf serine/threonine kinases has been the subject of intense research. Raf activates the MAPK kinase (MEK1/2) dual-specificity protein kinases, which then activate ERK1/2. The mutational activation of Raf in human cancers supports the importtant role of this pathway in human oncogenesis. Additionally, the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.

The serine/threonine protein kinase PKB/Akt is a crucial regulator of cell growth, proliferation, differentiation and apoptosis. Mitogenic signaling by receptor tyrosine kinases that increase phosphatidylinositol 3-kinase (PI3K) activity lead to activation of PKB/Akt which in turn triggers a number of responses like cell growth, survival and increased motility. Interactions between MAPK and PI3K/Akt pathways have also been reported (1).

There are a number of studies investigating the role of these signaling cascades in pituitary tumorigenesis. In somatolactotroph GH4C1 cell lines, both gsp oncogene and over-expression of wild-type Gsα protein was found to initiate a sustained MAPK ERK 1/2 activation (2). In a study performed in GH-secreting adenomas and non-functioning pituitary adenomas, the activation of G-protein-coupled receptors by neurohormones caused an increase in ERK 1/2 activity, while increasing cAMP by forskolin increased ERK 1/2 activity only in GH-omas (3). In a study by Muşat et al. Akt mRNA was found to be over-expressed and immunohistochemical expression of phosho-Akt was found to be higher in pituitary adenomas compared to normal pituitaries (4). In a knock-in mutant mouse model carrying a mutation in thyroid hormone receptor-β gene, spontaneous development of TSH-omas with accompanying activation of Akt and its downstream effectors were noted (5). In a recent study, mutations and amplifications in PI3K3CA gene of the PI3K/Akt pathway have been found in invasive pituitary tumors compared to noninvasive ones (6).

In conclusion, there are reports showing both MAPK and PI3K/Akt over-activation in pituitary tumors, however whether activation of these pathways are primary events or their activation results from upstream regulators of these pathways needs to be revealed.

Article tools

My recent searches

No recent searches.